<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992520</url>
  </required_header>
  <id_info>
    <org_study_id>CVIA 088</org_study_id>
    <nct_id>NCT04992520</nct_id>
  </id_info>
  <brief_title>Controlled Human Infection Model Challenge/Rechallenge</brief_title>
  <official_title>Controlled Human Infection Model Challenge/Rechallenge: Shigella Flexneri 2a and S. Sonnei Cross-protective Antigens Discovery in Healthy Adults in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University Center for Immunization Research (CIR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the shigellosis rate in subjects previously challenged with a&#xD;
      heterologous Shigella serotype to the attack rate in naïve subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center controlled human infection model (CHIM) study designed to assess the&#xD;
      cross-protective efficacy and markers of protection after challenge and heterologous&#xD;
      rechallenge with Shigella strains of different serotypes in naïve healthy adult volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 6, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Shigellosis</measure>
    <time_frame>11 days after challenge administration</time_frame>
    <description>-Severe diarrhea (≥6 loose [grade 3-5] stools within 24h or &gt;800 - 999 grams loose [grade 3-5] stools within any 24-hour window)&#xD;
OR&#xD;
-Moderate diarrhea (4 to 5 loose [grade 3-5] stools within 24h or 401-800 grams loose [grade 3-5] stools within any 24-hour window) with fever (Oral temperature of ≥101.2°F) OR with one or more moderate constitutional or enteric symptom OR ≥2 episodes of vomiting in a 24-hour period&#xD;
OR&#xD;
-Dysentery: ≥2 loose stools with gross blood (hemoccult positive) in 24 hours AND fever OR ≥1 moderate constitutional/enteric symptom OR ≥2 episodes of vomiting in 24 hours</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Shigellosis</condition>
  <arm_group>
    <arm_group_label>Group 1A: S. sonnei 53G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. sonnei 53G&#xD;
Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B: S. flexneri 2a 2457T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least 3 months after challenging Group 1A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. flexneri 2a&#xD;
Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A: S. flexneri 2a 2457T (1500 cfu)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. flexneri 2a&#xD;
Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B: S. sonnei 53G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least 3 months after challenging Group 2A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. sonnei 53G&#xD;
Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S. sonnei 53G</intervention_name>
    <description>Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast</description>
    <arm_group_label>Group 1A: S. sonnei 53G</arm_group_label>
    <arm_group_label>Group 2B: S. sonnei 53G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S. flexneri 2a 2457T</intervention_name>
    <description>Shigella flexneri strain 2457T (Lot 1617) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.</description>
    <arm_group_label>Group 1B: S. flexneri 2a 2457T</arm_group_label>
    <arm_group_label>Group 2A: S. flexneri 2a 2457T (1500 cfu)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults, male or female, aged 18 to 50 years (all inclusive) at the time of&#xD;
             enrollment.&#xD;
&#xD;
          2. General good health, without clinically significant medical history, physical&#xD;
             examination findings, or clinical laboratory abnormalities per judgment of PI.&#xD;
&#xD;
          3. Willingness to participate in the study after all aspects of the protocol have been&#xD;
             explained and written informed consent obtained.&#xD;
&#xD;
          4. Completion of a training session and demonstrated comprehension of the protocol&#xD;
             procedures and knowledge of Shigella-associated illness by passing a written&#xD;
             examination (70% passing score).&#xD;
&#xD;
          5. Availability for the study duration, including all planned follow-up visits.&#xD;
&#xD;
          6. Female participants must have a negative pregnancy test at screening and prior to each&#xD;
             challenge.&#xD;
&#xD;
          7. Female participants must agree to avoid pregnancy for 29 days following the last&#xD;
             challenge dose by use of an efficacious hormonal or barrier method of birth control&#xD;
             during the study. Abstinence is acceptable. Female participants unable to bear&#xD;
             children must have this documented (e.g., tubal ligation or hysterectomy).&#xD;
&#xD;
          8. Willingness to refrain from participation in a study of another investigational agent&#xD;
             for 90 days following the last challenge dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of a significant medical or psychiatric condition that in the opinion of the&#xD;
             investigator precludes participation in the study. Some medical conditions that are&#xD;
             adequately treated and stable would not preclude entry into the study.&#xD;
&#xD;
          2. Clinically significant abnormalities in screening on physical exam or screening&#xD;
             laboratory results as determined by PI or PI in consultation with the research monitor&#xD;
             and Sponsor.&#xD;
&#xD;
          3. Recent receipt of another investigational product (within 30 days before enrollment).&#xD;
&#xD;
          4. Positive enzyme-linked immunosorbent assay (ELISA) and confirmatory tests for human&#xD;
             immunodeficiency virus (HIV).&#xD;
&#xD;
          5. Positive hepatitis C (HCV) ELISA and confirmatory test (e.g., HCV ribonucleic acid&#xD;
             (RNA)).&#xD;
&#xD;
          6. Positive hepatitis B virus surface antigen (HBsAg) by ELISA.&#xD;
&#xD;
          7. Use of any medication that affects immune function (e.g., corticosteroids and others)&#xD;
             within 30 days preceding the first challenge or planned use during the active study&#xD;
             period (topical and ophthalmologic steroids are allowable).&#xD;
&#xD;
          8. Evidence of impaired immune function or immune compromise (known immunodeficiency&#xD;
             syndrome; either congenital, acquired, or iatrogenic; active autoimmune disease;&#xD;
             repeated serious infections without known cause).&#xD;
&#xD;
          9. IgA deficiency (serum IgA &lt; 7 mg/dL or below the limit of detection of the assay).&#xD;
&#xD;
         10. Positive blood test for HLA-B27.&#xD;
&#xD;
         11. Personal or family history of an inflammatory arthritis.&#xD;
&#xD;
         12. Currently pregnant or nursing.&#xD;
&#xD;
         13. Evidence of current alcohol or drug dependence, or history of dependence in the last 6&#xD;
             months.&#xD;
&#xD;
         14. Recent vaccination (including licensed vaccines) or receipt of an investigational&#xD;
             product (within 30 days before challenge through 90 days following the last challenge&#xD;
             dose). Annual influenza vaccine, an emergency authorized or licensed COVID-19 vaccine,&#xD;
             or a TdaP or TD booster may be administered beyond 30 days after each challenge.&#xD;
&#xD;
         15. Treatment with immunoglobulins or blood products within 3 months of challenge.&#xD;
&#xD;
         16. Current or prior history of inflammatory bowel disease or irritable bowel syndrome or&#xD;
             abnormal stool pattern (&gt;3/day or &lt;3/ week, or loose or liquid stools).&#xD;
&#xD;
         17. Chronic use of anti-diarrheal, anti-constipation, or antacid therapy; or use of these&#xD;
             medications in the 7 days prior to challenge.&#xD;
&#xD;
         18. Use of proton pump inhibitors or H2 blockers (H2-receptor antagonists) within 48 hours&#xD;
             prior to challenge.&#xD;
&#xD;
         19. Use of antibiotics within 7 days prior to challenge.&#xD;
&#xD;
         20. Known allergy to any 2 of the following antibiotics: ciprofloxacin,&#xD;
             trimethoprim-sulfamethoxazole, or penicillin.&#xD;
&#xD;
         21. Symptoms of travelers' diarrhea (TD) associated with travel to countries where&#xD;
             Shigella or other enteric infections are endemic (most of the developing world) within&#xD;
             3 years prior to challenge OR planned travel to endemic countries during the active&#xD;
             study period.&#xD;
&#xD;
         22. History of shigellosis, Shigella vaccination or challenge, or a laboratory worker with&#xD;
             known exposure to Shigella within the last 5 years.&#xD;
&#xD;
         23. Serum IgG titer &gt; 2500 to either Shigella flexneri 2a or Shigella sonnei LPS.&#xD;
&#xD;
         24. Any other criteria which, in the investigator's opinion, would compromise the ability&#xD;
             of the volunteer to participate in the study, the safety of the study, or the results&#xD;
             of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kawsar Talaat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kawsar Talaat, MD</last_name>
    <phone>240-432-2757</phone>
    <email>ktalaat@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivia Mihulka</last_name>
    <phone>443-547-0592</phone>
    <email>omihulk1@jhmi.edu</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

